BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

471 related articles for article (PubMed ID: 31620804)

  • 1. Clinical and Histological Characteristics of Mycosis Fungoides and Sézary Syndrome: A Retrospective, Single-centre Study of 43 Patients from Eastern Denmark.
    Nielsen PR; Eriksen JO; Wehkamp U; Lindahl LM; Gniadecki R; Fogh H; Fabricius S; Bzorek M; Ødum N; Gjerdrum LM
    Acta Derm Venereol; 2019 Dec; 99(13):1231-1236. PubMed ID: 31620804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mycosis fungoides and Sézary syndrome: Current challenges in assessment, management and prognostic markers.
    Hughes CF; Newland K; McCormack C; Lade S; Prince HM
    Australas J Dermatol; 2016 Aug; 57(3):182-91. PubMed ID: 25988337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now?
    Scarisbrick JJ; Kim YH; Whittaker SJ; Wood GS; Vermeer MH; Prince HM; Quaglino P
    Br J Dermatol; 2014 Jun; 170(6):1226-36. PubMed ID: 24641480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome.
    Benton EC; Crichton S; Talpur R; Agar NS; Fields PA; Wedgeworth E; Mitchell TJ; Cox M; Ferreira S; Liu P; Robson A; Calonje E; Stefanato CM; Wilkins B; Scarisbrick J; Wain EM; Child F; Morris S; Duvic M; Whittaker SJ
    Eur J Cancer; 2013 Sep; 49(13):2859-68. PubMed ID: 23735705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characteristics, prognostic factors, and survival of 393 patients with mycosis fungoides and Sézary syndrome in the southeastern United States: a single-institution cohort.
    Desai M; Liu S; Parker S
    J Am Acad Dermatol; 2015 Feb; 72(2):276-85. PubMed ID: 25458019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression.
    Kim YH; Liu HL; Mraz-Gernhard S; Varghese A; Hoppe RT
    Arch Dermatol; 2003 Jul; 139(7):857-66. PubMed ID: 12873880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal.
    Agar NS; Wedgeworth E; Crichton S; Mitchell TJ; Cox M; Ferreira S; Robson A; Calonje E; Stefanato CM; Wain EM; Wilkins B; Fields PA; Dean A; Webb K; Scarisbrick J; Morris S; Whittaker SJ
    J Clin Oncol; 2010 Nov; 28(31):4730-9. PubMed ID: 20855822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome. Definition of three distinctive prognostic groups.
    Sausville EA; Eddy JL; Makuch RW; Fischmann AB; Schechter GP; Matthews M; Glatstein E; Ihde DC; Kaye F; Veach SR
    Ann Intern Med; 1988 Sep; 109(5):372-82. PubMed ID: 3408055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome.
    Kim YH; Bishop K; Varghese A; Hoppe RT
    Arch Dermatol; 1995 Sep; 131(9):1003-8. PubMed ID: 7661601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycosis fungoides and the Sézary syndrome: pathology, staging, and treatment.
    Hoppe RT; Wood GS; Abel EA
    Curr Probl Cancer; 1990; 14(6):293-371. PubMed ID: 2245651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model.
    Scarisbrick JJ; Prince HM; Vermeer MH; Quaglino P; Horwitz S; Porcu P; Stadler R; Wood GS; Beylot-Barry M; Pham-Ledard A; Foss F; Girardi M; Bagot M; Michel L; Battistella M; Guitart J; Kuzel TM; Martinez-Escala ME; Estrach T; Papadavid E; Antoniou C; Rigopoulos D; Nikolaou V; Sugaya M; Miyagaki T; Gniadecki R; Sanches JA; Cury-Martins J; Miyashiro D; Servitje O; Muniesa C; Berti E; Onida F; Corti L; Hodak E; Amitay-Laish I; Ortiz-Romero PL; Rodríguez-Peralto JL; Knobler R; Porkert S; Bauer W; Pimpinelli N; Grandi V; Cowan R; Rook A; Kim E; Pileri A; Patrizi A; Pujol RM; Wong H; Tyler K; Stranzenbach R; Querfeld C; Fava P; Maule M; Willemze R; Evison F; Morris S; Twigger R; Talpur R; Kim J; Ognibene G; Li S; Tavallaee M; Hoppe RT; Duvic M; Whittaker SJ; Kim YH
    J Clin Oncol; 2015 Nov; 33(32):3766-73. PubMed ID: 26438120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of CCR3 and CCR4 Suggests a Poor Prognosis in Mycosis Fungoides and Sézary Syndrome.
    Shono Y; Suga H; Kamijo H; Fujii H; Oka T; Miyagaki T; Shishido-Takahashi N; Sugaya M; Sato S
    Acta Derm Venereol; 2019 Jul; 99(9):809-812. PubMed ID: 31045236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes and prognostic factors in African American and black patients with mycosis fungoides/Sézary syndrome: Retrospective analysis of 157 patients from a referral cancer center.
    Geller S; Lebowitz E; Pulitzer MP; Horwitz SM; Moskowitz AJ; Dusza S; Myskowski PL
    J Am Acad Dermatol; 2020 Aug; 83(2):430-439. PubMed ID: 31499157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mycosis fungoides and Sézary syndrome: Australian clinical practice statement.
    Bhabha FK; McCormack C; Wells J; Campbell BA; Newland K; Lade S; Buelens O; Joske D; Shortt J; Mapp S; Radeski D; Hertzberg M; Khot A; Van Der Weyden C; Khoo C; Hawkes E; Prince HM
    Australas J Dermatol; 2021 Feb; 62(1):e8-e18. PubMed ID: 33368169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transformation of Mycosis Fungoides/Sezary Syndrome: Clinical Characteristics and Prognosis.
    Vural S; Akay BN; Botsalı A; Atilla E; Parlak N; Okçu Heper A; Şanlı H
    Turk J Haematol; 2018 Mar; 35(1):35-41. PubMed ID: 28533196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leonine facies (LF) and mycosis fungoides (MF): A single-center study and systematic review of the literature.
    Brown DN; Wieser I; Wang C; Dabaja BS; Duvic M
    J Am Acad Dermatol; 2015 Dec; 73(6):976-86. PubMed ID: 26476898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of cutaneous lymphoma international prognostic index (CLIPI) for mycosis fungoides and Sézary syndrome.
    Danish HH; Liu S; Jhaveri J; Flowers CR; Lechowicz MJ; Esiashvili N; Khan MK
    Leuk Lymphoma; 2016 Dec; 57(12):2813-2819. PubMed ID: 27104864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcomes of 1,263 patients with mycosis fungoides and Sézary syndrome from 1982 to 2009.
    Talpur R; Singh L; Daulat S; Liu P; Seyfer S; Trynosky T; Wei W; Duvic M
    Clin Cancer Res; 2012 Sep; 18(18):5051-60. PubMed ID: 22850569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The MicroRNA Expression Profile Differs Between Erythrodermic Mycosis Fungoides and Sézary Syndrome.
    Rittig AH; Lindahl LM; Johansen C; Celis P; Ødum N; Iversen L; Litman T
    Acta Derm Venereol; 2019 Nov; 99(12):1148-1153. PubMed ID: 31453630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis.
    Diamandidou E; Colome-Grimmer M; Fayad L; Duvic M; Kurzrock R
    Blood; 1998 Aug; 92(4):1150-9. PubMed ID: 9694702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.